{"id":"cpl500036-high-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CPL500036 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. The high dose formulation is likely used to achieve a more rapid or potent effect.","oneSentence":"CPL500036 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:26.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05278156","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2021-05-19","conditions":"Schizophrenia","enrollment":189},{"nctId":"NCT05297201","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2021-11-02","conditions":"Parkinson Disease, Dyskinesia, Medication-Induced","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CPL500036 - high dose","genericName":"CPL500036 - high dose","companyName":"Celon Pharma SA","companyId":"celon-pharma-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CPL500036 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}